Autophagy

Autophagy ("self-eating") is the process by which cells break down and recycle damaged proteins, protein aggregates, and organelles inside double-membraned vesicles called autophagosomes that fuse with lysosomes. Macroautophagy, the main form studied in aging, is induced when mTORC1 activity falls and AMPK activity rises, typically during fasting, exercise, or nutrient scarcity [1]. Yoshinori Ohsumi won the 2016 Nobel Prize in Physiology or Medicine for identifying the core autophagy genes in yeast.

Autophagic flux declines with age across tissues in rodents, and restoring it, genetically or with drugs like rapamycin and spermidine, extends lifespan in mice and delays markers of cardiac and neuronal aging [2]. A 2021 review in Nature Aging catalogued dozens of interventions (caloric restriction, fasting, exercise, spermidine, resveratrol) that converge on autophagy induction as a shared mechanism for lifespan extension in model organisms [2]. In humans, a registered clinical trial (NCT04842864) is tracking the time course of fasting-induced autophagy using LC3 markers in blood cells, aiming to establish how long a human fast takes to meaningfully increase autophagic flux [3]. Results from that specific trial were not yet available as of this writing.

What the evidence does not show: there is no validated, easily measured blood biomarker of autophagic flux in living humans comparable to what is used in mouse tissue biopsies, so most human autophagy claims are inferred from indirect markers (LC3-II, p62/SQSTM1 in peripheral blood cells) rather than direct organ-level measurement. No RCT has shown that pharmacologically boosting autophagy changes human mortality or disease incidence.

Bryan Johnson's Blueprint protocol includes daily time-restricted eating and periodic longer fasts intended partly to induce autophagy, alongside spermidine supplementation; these are self-reported, n=1 interventions tracked against his blood biomarker panel rather than validated against a direct autophagy assay [4].

Critics note that "autophagy activator" has become a loose marketing term applied to supplements with only indirect or mouse-only evidence of raising human autophagic flux; biogerontologist Matt Kaeberlein has pointed out that most consumer-facing autophagy claims rest on rodent dosing scaled inconsistently to humans, not on direct human tissue measurement [2]. A separate review focused specifically on the balance of benefit and harm noted that autophagy is not uniformly protective: in some cancer contexts and some models of neurodegeneration, excessive or dysregulated autophagy can be harmful rather than protective, complicating the simple "more autophagy is better" framing that supplement marketing often uses [5]. A broader synthesis of healthy-aging autophagy research reached a similar conclusion, that autophagy's net effect depends heavily on tissue, timing, and degree of induction rather than being a single dial to turn up [6].

The plain takeaway: autophagy induction is one of the best-supported shared mechanisms behind lifespan-extending interventions in animals, but human measurement of the pathway itself remains crude, and its effects are not uniformly beneficial across every tissue and context.